Biotech company focused on developing and commercializing vaccines for infectious diseases.
Valneva SE is a specialized vaccine company dedicated to advancing prophylactic vaccines for infectious diseases with significant unmet medical needs. Founded in 1998 and based in Saint-Herblain, France, the company focuses on developing and commercializing a diverse portfolio of vaccines tailored for global health challenges. Among its flagship products are IXIARO, an inactivated Japanese encephalitis vaccine designed for travelers, and DUKORAL, an oral vaccine targeting diarrhea caused by Vibrio cholera and heat-labile toxin producing Enterotoxigenic Escherichia coli.
Valneva SE is also at the forefront of vaccine innovation with its COVID-19 candidate, VLA2001, aimed at combatting the SARS-CoV-2 virus. Additionally, the company is advancing VLA15, a vaccine candidate targeting Borrelia, and VLA1553, currently in Phase III trials for the prevention of chikungunya virus infection. Its products are marketed across the United States, Canada, Europe, and other international markets, reflecting its global reach and commitment to addressing public health challenges worldwide.
In strategic collaborations, Valneva SE partners with Pfizer, Inc. for the co-development and commercialization of a Lyme disease vaccine, underscoring its collaborative approach to advancing vaccine development. Furthermore, its partnership with Instituto Butantan focuses on the development, manufacturing, and distribution of a single-shot chikungunya vaccine, highlighting its efforts to expand access to innovative vaccines across diverse geographies. Through these initiatives, Valneva SE continues to innovate and deliver impactful solutions in the field of infectious disease prevention.